Stockreport

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates [Yahoo! Finance]

CG Oncology, Inc. - Common stock  (CGON) 
PDF CG Oncology Inc. PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 COR [Read more]